TY - JOUR T1 - Response to: ‘COVID-19 in paediatric rheumatology patients treated with b/tsDMARDs: a cross-sectional patient survey study’ by Cuceoglu <em>et al</em> JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis DO - 10.1136/annrheumdis-2020-218364 SP - annrheumdis-2020-218364 AU - Carlo Salvarani AU - Gianluigi Bajocchi AU - Pamela Mancuso AU - Elena Galli AU - Francesco Muratore AU - Paolo Giorgi Rossi Y1 - 2020/07/05 UR - http://ard.bmj.com/content/early/2020/07/05/annrheumdis-2020-218364.abstract N2 - We appreciated the comment from Cuceoglu et al 1 in response to our paper on the susceptibility and severity of COVID-19 in a population-based cohort of patients treated with biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs).2 We did not observe patients with COVID-19 &lt;45 years in our cohort of 1195 cases with autoimmune diseases treated with b/tsDMARDs in Reggio Emilia area. Confirming our results, the authors did not observe cases of COVID-19 in a series of 173 Turkish paediatric patients with rheumatological conditions … ER -